J S Hiremath
Overview
Explore the profile of J S Hiremath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
25
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sethi R, Hiremath J, Ganesh V, Banerjee S, Shah M, Mehta A, et al.
Cardiovasc Ther
. 2021 Jul;
2021:6622651.
PMID: 34257706
Objectives: To assess mean systolic and diastolic blood pressure (SBP and DBP) levels in patients ≥50 years with uncontrolled hypertension (HTN) and evaluate the correlation between BP and stroke risk....
2.
Hiremath J, Chokalingam K, Mathan G, Reddy P, Sharma A, Dhawan S, et al.
J Assoc Physicians India
. 2019 Jul;
66(12):11-12.
PMID: 31313548
Objective: Triple drug combination has shown to be effective in controlling blood pressure (BP) with low rates of drug-related side effects. The present study was conducted to compare the efficacy...
3.
Trailokya A, Hiremath J
J Assoc Physicians India
. 2018 Oct;
66(4):85-90.
PMID: 30347966
Atrial fibrillation (AF) is commonly occurring arrhythmia in clinical practice. AF is easy to recognize but difficult to treat. Stroke is the most devastating complication of AF and is associated...
4.
Trailokya A, Hiremath J, Sawhney J, Mishra Y, Kanhere V, Srinivasa R, et al.
J Assoc Physicians India
. 2016 Oct;
64(2):88-93.
PMID: 27730796
Anticoagulant treatment is required for the treatment and prevention of thromboembolic disorders. Vitamin K antagonists are commonly used oral anticoagulants worldwide. Acenocoumarol is mono-coumarin derivative with racemic mixture of R...
5.
Iyengar S, Nair T, Hiremath J, Jadhav U, Katyal V, Kumbla D, et al.
Indian Heart J
. 2013 Sep;
65(4):436-41.
PMID: 23993004
Objective: To study the efficacy and safety of single intravenous bolus administration of indigenously developed tenecteplase (TNK-tPA) in the management of patients with ST-elevation myocardial infarction (STEMI) in clinical practice....
6.
Iyengar S, Nair T, Hiremath J, Jadhav U, Katyal V, Kumbla D, et al.
Indian Heart J
. 2012 Nov;
63(1):104-7.
PMID: 23189874
Objective: To study the efficacy and safety of single intravenous bolus administration of indigenously developed tenecteplase in the management of patients presenting with ST-elevation myocardial infarction in clinical practice. Methods:...
7.
Hiremath J
J Assoc Physicians India
. 2012 May;
59 Suppl:49-50.
PMID: 22624282
Acute myocardial infarction has two main treatment modalities in the form of direct angioplasty (PAMI) and intravenous thrombolysis. PAMI is statistically clearly superior to intravenous thrombolysis. However, as ground reality...
8.
Iyengar S, Nair T, Sathyamurthy I, Hiremath J, Jadhav U, Kumbla D, et al.
Indian Heart J
. 2010 Jul;
61(5):480-1.
PMID: 20635768
Objective: to study the efficacy and safety of indigenously developed tenecteplase injection in the management of Indian STEMI patients in clinical practice. Methods: post-licensure, observational, prescription event monitoring study. Results:...
9.
Mardikar H, Hiremath M, Moliterno D, Mathew R, Arora R, Deo D, et al.
Am Heart J
. 2007 Jul;
154(2):344.e1-5.
PMID: 17643586
Background: Optimal inhibition of platelet aggregation (IPA) may afford greater protection against ischemic events during percutaneous coronary intervention (PCI). The objective of this study was to test several antiplatelet regimens...
10.
Diwedi S, Hiremath J, Kerkar P, Reddy K, Manjunath C, Ramesh S, et al.
Indian J Med Sci
. 2005 Jun;
59(5):200-7.
PMID: 15985728
Background: Streptokinase is the most widely used thrombolytic agent and can now be made using recombinant DNA technology. The present trial was initiated to assess an indigenous recombinant streptokinase (Shankinase,...